2-氯-7-甲氧基-4-甲基喹啉 | 97892-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-氯-7-甲氧基-4-甲基喹啉
• 英文名称: 2-chloro-7-methoxy-4-methylquinolin
• 英文别名: 2-cloro-4-metil-7-metossichinolina；2-chloro-7-methoxy-4-methyl-quinoline；2-Chlor-7-methoxy-4-methyl-chinolin；2-chloro-7-methoxy-4-methylquinoline
• CAS: 97892-67-6
• 化学式: C₁₁H₁₀ClNO
• mdl: MFCD00711757
• 分子量: 207.659
• InChiKey: SMJPQHMCVFWKMI-UHFFFAOYSA-N

物化性质

• 熔点：
  111-113℃
• 沸点：
  333.4±37.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2-氯-7-甲氧基-4-甲基喹啉 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 10.0h， 生成 2-肼基-7-甲氧基-4-甲基喹啉
  参考文献：
  名称：

  Pellerano; Savini; Brizzi, Farmaco, Edizione Scientifica, 1985, vol. 40, # 7, p. 486 - 492

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 五氯化磷 、 三氯氧磷 作用下， 生成 2-氯-7-甲氧基-4-甲基喹啉
  参考文献：
  名称：

  Spaeth; Brunner, Chemische Berichte, 1924, vol. 57, p. 1246

  摘要：

  DOI：

文献信息

• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。
• Continuous flow Negishi cross-couplings employing silica-supported Pd-PEPPSI–IPr precatalyst
  作者：Gregory A. Price、Andrew R. Bogdan、Ana L. Aguirre、Toshiyuki Iwai、Stevan W. Djuric、Michael G. Organ

  DOI：10.1039/c6cy00331a

  日期：——

  Pd-PEPPSI–IPr complex prepared via azide–alkyne cycloaddition is described. The complex was immobilised onto silica gel and applied as a heterogeneous catalyst in the Negishi reaction. The catalyst was active in both batch and continuous flow operation and was particularly effective for the coupling of heteroaryl chlorides. Long-term continuous flow experiments demonstrated good catalyst activity over

  三乙氧基甲硅烷的合成官能化的Pd-PEPPSI -的IPr复杂制备经由叠氮化物-炔环加成进行说明。将该配合物固定在硅胶上，并在Negishi反应中用作非均相催化剂。该催化剂在间歇和连续流动操作中均具有活性，并且对于杂芳基氯化物的偶联特别有效。长期连续流实验表明，在15个小时内，催化剂具有良好的活性。
• Therapeutic agents I
  申请人：Evertsson Emma

  公开号：US20070185079A1

  公开（公告）日：2007-08-09

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的公式(I)，制备这些化合物的过程，它们在治疗肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫和相关疾病以及神经系统疾病如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛有关的疾病中的应用，以及含有它们的制药组合物。
• Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure–activity relationship studies
  作者：Sandra Gemma、Luisa Savini、Maria Altarelli、Pierangela Tripaldi、Luisa Chiasserini、Salvatore Sanna Coccone、Vinod Kumar、Caterina Camodeca、Giuseppe Campiani、Ettore Novellino、Sandra Clarizio、Giovanni Delogu、Stefania Butini

  DOI：10.1016/j.bmc.2009.06.051

  日期：2009.8

  A series of 4-quinolylhydrazones was synthesized and tested in vitro against Mycobacterium tuberculosis. At a concentration of 6.25 mu g/mL, most of the newly synthesized compounds displayed 100% inhibitory activity against M. tuberculosis in cellular assays. Further screening allowed the identification of very potent antitubercular agents. Compound 4c was also tested in a time-course experiment and against mtb clinical isolates, displaying interesting results. (C) 2009 Elsevier Ltd. All rights reserved.
• Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists
  作者：Fabrizio Giordanetto、Olle Karlsson、Jan Lindberg、Lars-Olof Larsson、Anna Linusson、Emma Evertsson、David G.A. Morgan、Tord Inghardt

  DOI：10.1016/j.bmcl.2007.05.034

  日期：2007.8

  We herein report the optimization of cyclopentane- and cyclohexane-1,3-diamine derivatives as novel and potent MCH-R I antagonists. Structural modifications of the 2-amino-quinoline and thiophene moieties found in the initial lead compound served to improve its metabolic stability profile and MCH-RI affinity, and revealed unprecedented SAR when compared to other 2-aminoquinoline-containing NICH-R1 antagonists. (c) 2007 Elsevier Ltd. All rights reserved.